Lung Cancer | Leora Horn, MD, MSc and Yanjun Ma, MD

Research To Practice | Oncology Videos

Visiting Professors: Lung Cancer Edition — Part 2: Our discussion with Drs Horn and Ma highlights the following topics as well as cases from Dr Ma’s practice:

• Case: A woman in her mid-70s with Stage IV lung adenocarcinoma and a PD-L1 TPS of 70% experiences a pathologic fracture of the right femur while receiving first-line pembrolizumab (00:00)
• Pembrolizumab monotherapy versus carboplatin/pemetrexed/pembrolizumab as first-line therapy for patients with metastatic NSCLC and a high TPS (02:30)
• Radiation necrosis as a potential cause of pathologic fractures (05:18)
• Thyroid dysfunction and pancreatitis associated with pembrolizumab (08:12)
• Case: A man in his early 50s with metastatic lung cancer of ambiguous histology experiences a dramatic response to first-line nab paclitaxel/carboplatin (11:11)
• Utility of liquid biopsies in therapeutic decision-making for patients with metastatic lung cancer (13:03)
• Therapy for patients with metastatic lung cancer and CNS metastases (15:11)
• Therapeutic approach for patients with metastatic lung cancer of undetermined histology (20:30)
• Second-line therapy for patients with metastatic lung cancer (22:41)
• Case: A woman in her mid-80s with metastatic lung adenocarcinoma and a PD-L1 TPS of 30% receives pemetrexed/pembrolizumab and experiences dyspnea (28:14)
• Perspective on the approach to metastatic lung adenocarcinoma in elderly patients (30:52)
• Efficacy of ramucirumab as second-line therapy for patients with metastatic NSCLC (36:24)
• REVEL: Results of a Phase III trial evaluating the addition of ramucirumab to docetaxel after disease progression on platinum-based therapy for patients with Stage IV NSCLC (37:44)
• Comparison of the activity and tolerability of ramucirumab to that of bevacizumab in patients with metastatic squamous cell carcinoma of the lung (40:11)
• Ongoing clinical investigation of novel combination approaches with immune checkpoint inhibitors and anti-angiogenic agents (41:49)
• Case: A man in his mid-70s, a former smoker, with Stage III NSCLC initially treated with adjuvant chemoradiation therapy develops metastatic disease and is found to have a RET tumor mutation (43:40)
• Effects of tumor mutation burden and PD-L1 expression on response to immune checkpoint inhibitors (47:32)
• Perspective on the use of targeted therapy as first-line treatment for patients with metastatic NSCLC (49:32)
• Sequencing targeted therapy and immune checkpoint inhibitors for patients with metastatic NSCLC and actionable tumor mutations (51:08)
• Case: A woman in her early 60s with lung adenocarcinoma and oligometastatic disease in the brain receives first-line chemoradiation therapy (56:39)
• Cardiomyopathy associated with checkpoint inhibitor therapy (1:00:08)
• Prolonged responses to anti-PD-1/PD-L1 antibodies after cessation of therapy (1:03:27)
• PD-L1 expression as a predictor of response to immune checkpoint inhibitors (1:07:40)
• Case: A man in his early 70s with metastatic NSCLC develops a severe carboplatin-related allergy during treatment with carboplatin/nab paclitaxel/pembrolizumab (1:09:41)
• Benefits of early palliative care in the management of metastatic NSCLC (1:15:22)

CME information and select publications